When should I increase my Wegovy dose — and when should I wait?

You're four weeks in and wondering whether it's time to go up

Picture this: you started Wegovy at 0.25 mg, got through the first few weeks with some nausea, and now things feel more manageable. The four-week mark arrives and you're asking yourself whether you should increase to 0.5 mg. The honest answer is that four weeks is when a move can happen, not when it must. The Wegovy titration pathway is built around roughly monthly steps, but the word "roughly" is doing real work there.

Your prescriber is looking for two things before approving a dose increase: that the current dose is well tolerated, and that there is no clinical reason to pause. Well tolerated means that any gastrointestinal side effects (nausea, loose stools, reflux, that heavy feeling after eating) have largely settled. If you are still feeling rough at week four, the right move is usually to stay put for another week or two, then review again. Pushing ahead when your body is still adjusting tends to make the next dose feel worse, not better.

The clinical thinking behind semaglutide dose increases is consistent across the evidence: gradual titration reduces the severity of side effects over the course of treatment. Rushing that process does not speed up results; it often slows them down by making the medicine harder to stay on. NHS guidance supports this patient-led, prescriber-confirmed approach throughout the schedule.

What "tolerating the dose well" actually looks like in practice

This phrase gets used a lot, but what does it mean in the day-to-day? Broadly, it means that any side effects from the current dose are no longer affecting your quality of life in a significant way. A mild awareness of fullness sooner than usual, or the occasional twinge of nausea in the first day or two after an injection, usually falls within acceptable. Frequent vomiting, unable-to-eat nausea lasting several days, or significant diarrhoea does not.

It also means you have actually been injecting consistently at the prescribed interval. Missing doses, or spacing them out to avoid side effects, resets your body's adjustment process. If you find yourself delaying injections because you dread how they make you feel, that is a conversation to have with your prescriber before any increase, not something to push through quietly.

We understand that sitting at a lower dose can feel frustrating, especially if you were hoping for faster progress. That is a very human reaction, and our prescribers hear it regularly. The reassurance is that the weight-loss effect builds across the full titration journey, not just at the top dose. Many people find meaningful results begin well before 2.4 mg. You can read more about how the different Wegovy dose levels work and what to expect at each stage.

When the schedule slows down, and that's the right call

Some people reach 2.4 mg in around five months. Others take longer, and that is entirely appropriate. The schedule is a framework, not a race. There are specific situations where your prescriber will recommend staying at a lower dose for an extended period, or even stepping back down temporarily.

Illness is the most common one. A vomiting bug, surgery, or a period of significant stress can all affect how your body handles a GLP-1 medicine. If you have been unwell, tell your prescriber before they authorise a dose increase. Similarly, if you have recently started a new medication, your prescriber needs to know, some interactions affect how well Wegovy is absorbed or how your body responds to it.

There is also the question of what happens at the highest dose. Under the Wegovy milligram dose pathway, 2.4 mg has been the standard maintenance level, though the MHRA approved a 7.2 mg option in early 2026 for adults with obesity (BMI 30 or above) who meet the clinical criteria. Whether that higher maintenance dose is appropriate for you is a decision made with your prescriber based on your individual response to treatment and your medical history, it is not something to request simply because it exists.

If you are considering the private route and want a prescriber to review where you are in your titration, a free consultation with the nume clinical team gives you a same-day clinical review by a GPhC-registered prescriber, with no waiting list. The NHS guidance on weight-management injections and the NHS semaglutide page both cover the same titration principles if you want an independent reference point.

The role of cost in titration decisions, worth being honest about

There is a practical dimension to this that is worth naming plainly. Some people stay at a lower dose longer than their prescriber recommends because the higher doses cost more each month. That is understandable. But using the medicine at a sub-therapeutic dose for cost reasons, without telling your prescriber, is not a safe workaround, it changes the clinical picture they are working from. If cost is a genuine barrier to titrating properly, say so. A good prescriber would rather know and help you plan than have you make dose decisions quietly on your own.

If you want to understand how Wegovy pricing works in the UK across doses and providers, that page sets out the full picture without any surprises. Separately, questions about how frequently Wegovy dose increases are appropriate come up in consultations often, the short version is that more frequent than every four weeks is not recommended, and less frequent is sometimes exactly right.

If you are just starting out and wondering about the process from the very beginning, the guidance on taking your first Wegovy dose covers what to expect before the titration schedule begins.